UNSPSC 51422356: Methylprednisolone sodium succinate

This classification denotes a therapeutic glucocorticoid with the molecular formula C26H33O8.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LEC9GKY20K, chemically known as 1,4-butanedioic acid (succinic acid) but more generally known as methylprednisolone sodium succinate, which bears US NIH Compound Identifier 1110. European Medicines Agency schedules Methylprednisolone sodium succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14562MIG.

UNSPSC 51422356 Methylprednisolone sodium succinate is a Commodity code that, based on recent state and local procurement activity, covers pharmaceutical products and related health system procurement rather than the single steroid formulation the code name suggests. State and local health agencies, counties, and health commissions are using this code to solicit a broader range of pharmaceutical and drug-management products, including naloxone, safe drug deactivation systems, and direct-to-manufacturer prescription fulfillment programs. The issuing bodies include county health departments, state health and human services commissions, and community health agencies that manage pharmacy benefits, opioid-response programs, and controlled-substance inventory systems. Scope typically involves annual or ongoing supply contracts with quarterly or regular delivery schedules, unit-based pricing, shipping and logistics included in vendor proposals, and compliance with federal funding requirements when applicable.

Recent activity appears concentrated in Florida and Texas. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, through competitive sealed bidding via the county e-Procurement Portal. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 as a preliminary market-intelligence solicitation to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state-level interest in direct manufacturer contracting models outside traditional pharmacy benefit manager arrangements. The code shows limited recent activity nationally, with no visible opportunities posted under the nominal methylprednisolone name itself, suggesting that state and local procurement offices may be tagging broader pharmaceutical and drug-management programs under this code inconsistently.